Arrowhead Research | ARWR - Cash And Equivalent

Stock Price
76.67
Daily Change
-3.02 -3.79%
Monthly
12.78%
Yearly
388.03%
Q2 Forecast
75.13

Arrowhead Research reported $201.64M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.91B 687M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
TG Therapeutics USD 442.21M 242.7M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026